Ocular surface changes induced by topical application of latanoprost and timolol: a short-term study in glaucomatous patients with and without allergic conjunctivitis

Costagliola, Ciro; Prete, Antonio; Incorvaia, Carlo; Fusco, Rosa; Parmeggiani, Francesco; Giovanni, Alfredo Di

doi:10.1007/s004170100328

Cited by 51 publications

(38 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…3) Pisella et al 2004). Furthermore, the two chemokine receptors CCR4 and CCR5 were also found to be over-expressed in glaucoma patients receiving longterm treatment (Costagliola et al 2001), suggesting that the chronic use of antiglaucoma topical drugs induces a complex network of inflammatory reactions.…”

Section: Conjunctiva and Corneamentioning

confidence: 99%

“…The conjunctival cytology specimens of patients on longterm antiglaucoma medication also have distinct characteristics, including epithelial keratinization, squamous metaplasia and a reduction in the number of goblet cells (Table 2) (Costagliola et al 2001). Histomorphological changes to the epithelium can appear as early as 2 weeks after the start of antiglaucoma treatment (Lewis et al 2007).…”

Section: Conjunctiva and Corneamentioning

confidence: 99%

See 1 more Smart Citation

Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma

Baudouin

2008

Acta Ophthalmologica

231

146

View full text Add to dashboard Cite

ABSTRACT.Antiglaucoma medications are often associated with ocular adverse reactions such as dry eye, and burning or stinging sensations. These undesirable effects may lead to treatment discontinuation and reduced quality of life in patients with glaucoma. Antiglaucoma medications usually contain benzalkonium chloride (BAK) as a preservative. Animal studies, in vitro studies and in vivo experiments have demonstrated various adverse effects of BAK. Clinical studies have also shown an increased incidence of adverse events with BAK and have demonstrated that the withdrawal of preservatives reduces these effects. Collectively, these data suggest that preservative-free antiglaucoma treatments have clinically relevant benefits for patients.

show abstract

Section: Conjunctiva and Corneamentioning

confidence: 99%

Section: Conjunctiva and Corneamentioning

confidence: 99%

Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma

Baudouin

2008

Acta Ophthalmologica

231

146

View full text Add to dashboard Cite

show abstract

“…All eyedrops can cause some local adverse events, but with variable frequencies on the basis of individual susceptibility. They may induce pain on instillation, allergic reactions, delayed healing response, punctate keratitis, altered lacrimal secretion, disturbed accommodation and local pigmentation, especially after prolonged use [9, 10]. Local side effects of antiglaucomatous drugs may have a negative effect both on the compliance of the patient and the success of subsequent filtrating surgery [11,12,13,14] and may cause some other pathologies such as dry eye.…”

Section: Introductionmentioning

confidence: 99%

Comparison of Ocular Surface Side Effects of Topical Travoprost and Bimatoprost

Alagöz

Bayer²,

Boran³

et al. 2008

Ophthalmologica

View full text Add to dashboard Cite

Purpose: To compare the subjective symptoms, conjunctival hyperemia, tearing response and conjunctival cytological changes secondary to topical administration of bimatoprost and travoprost for 6 months. Methods: Newly diagnosed primary open-angle glaucoma patients were randomly prescribed bimatoprost (35 cases) or travoprost (42 cases). Two patients in each group were excluded because they did not appear at their appointments regularly. Thus, 33 and 40 patients completed the study in the bimatoprost and travoprost groups, respectively. Redness, itching, foreign-body sensation, pain and discomfort were assessed by a questionnaire, and patients were examined for conjunctival hyperemia. Schirmer’s I and break-up time tests were performed, and impression cytology of conjunctiva was evaluated. Results: Subjective symptoms were similar in both groups. The only subjective symptom that changed significantly was redness. The change in conjunctival hyperemia along the study period correlated with the patient-reported redness in both groups, being highest on day 30. Schirmer’s test I and break-up time did not change with time and were similar in both groups. The impression cytology grade increased with time in both groups with the only significant difference between groups on day 90 (higher in the bimatoprost group). Conclusion: We observed conjunctival hyperemia as the most common side effect of bimatoprost and travoprost. Tear film functions were not affected by these drugs while cytological alterations were.

show abstract

“…For example, differences in ocular surface side effects of latanoprost and timolol have been reported, although this is controversial among different studies. 51,52 Future studies may be warranted to evaluate TFO variances with different types of anti-glaucoma medication use. In addition, we did not evaluate number of instillations of medications per day or the time of last use.…”

Section: Discussionmentioning

confidence: 99%

Effect of chronic anti-glaucoma medications and trabeculectomy on tear osmolarity

Lee

Wong

Chua

et al. 2013

Eye

View full text Add to dashboard Cite

Purpose To evaluate the tear film osmolarity (TFO) and ocular surface clinical signs and symptoms in chronically medicated glaucoma patients and post-trabeculectomy patients. Methods This is a single-center, prospective case-controlled study. One-hundred and thirty eyes of 130 participants aged Z45 years were included (49 normal controls, 50 glaucoma patients on chronic preserved antiglaucoma medication Z6 months, and 31 post-trabeculectomy patients not on medication Z6 months). TFO, tear break-up time (TBUT), Schirmer's test I and dry eye symptoms were evaluated. Data from both groups of glaucoma patients were compared with age and sex-matched controls. Logistic regression was performed to calculate the odds ratios. Results Mean TFO in the three groups were 301.4 ± 7.7, 307.0 ± 9.3, and 307.4 ± 11.6 mOsm/l, respectively. Compared with normal controls, chronically medicated glaucoma patients and post-trabeculectomy patients were more likely to have a raised TFO, with odds ratios (95% CI) of 4.43 (1.74-11.32) and 2.76 (1.02-7.94), respectively. Both groups of glaucoma patients were also more likely to experience dry eye symptoms, with ORs of 4.72 (1.92-11.59) and 4.24 (1.54-11.72). There was no significant difference in TFO and symptoms between both groups of glaucoma patients, and in TBUT and Schirmer's test across all three groups. Conclusions Patients on chronic topical antiglaucoma medication and posttrabeculectomy patients were more likely to have raised TFO and dry eye symptoms, suggesting significant ocular surface disease. Glaucoma practitioners should be aware that dry eye symptoms and raised TFO may occur in the absence of TBUT and Schirmer's test abnormality.

show abstract

Ocular surface changes induced by topical application of latanoprost and timolol: a short-term study in glaucomatous patients with and without allergic conjunctivitis

Cited by 51 publications

References 34 publications

Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma

Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma

Comparison of Ocular Surface Side Effects of Topical Travoprost and Bimatoprost

Effect of chronic anti-glaucoma medications and trabeculectomy on tear osmolarity

Contact Info

Product

Resources

About